middle.news
CHMP Recommends EU Approval for Neuren’s DAYBU to Treat Rett Syndrome
7:43am on Monday 29th of June, 2026 AEST
•
Pharmaceuticals
Read Story
CHMP Recommends EU Approval for Neuren’s DAYBU to Treat Rett Syndrome
7:43am on Monday 29th of June, 2026 AEST
Key Points
CHMP issues positive opinion for DAYBU® in Rett syndrome
Potential first EU-approved treatment for Rett syndrome symptoms
Neuren to receive US$35 million on first EU sale plus royalties
European Commission decision expected in coming months
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neuren Pharmaceuticals (ASX:NEU)
OPEN ARTICLE